CDK4 and prostate carcinoma: This suggests that additional molecular mechanisms may lead to the dysfunction of the cyclin D-CDK4/6-RB pathway in prostate cancer, ultimately resulting in the same biological consequence: progression through the G1/S phase of the cell cycle.